Hookipa Pharma Inc (HOOK) Stock Price, Quote & News

Company Profile

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 431 890 6360

Website: www.hookipapharma.com

Address:

350 Fifth Avenue, 72nd Floor Suite 7240, New York, United States

superjeffy Jul. 2 at 5:56 PM

$HOOK or cash out now and get your whole $1.28 a share now

1 · Reply

Wildsens Jun. 30 at 9:31 PM

$HOOK New PR. It takes 3 years and you get 1.28 - 1.72 (probably). https://ir.hookipapharma.com/static-files/11f0658d-d3b3-44ca-aaf1-b7a89d34500d#page48

1 · Reply

DollaNugs Jun. 30 at 2:13 PM

$HOOK

0 · Reply

dcljr521 Jun. 30 at 1:41 PM

$HOOK is there any hope left?

0 · Reply

wyoming2020 Jun. 28 at 7:44 PM

$PDSB the circulating dna data is very strong on the MD Anderson trial and the OS is going to be impressive. Little doubt this drug is commercialised but the company is out of money, essentially <$250M. You need a fortune to compete here. Gilead took $HOOK for free essentially. There is little hope the company can afford the $100M+ milestones to Merck Gaa, whom they purchased the rights from years ago. I think we see a return of asset and why I am long $MRK as well. Still here. I'll die on the hill but I am hedging (doubling loss😂 w MRK purchase)

3 · Reply

Wildsens Jun. 16 at 8:21 PM

$HOOK More info: https://ir.hookipapharma.com/static-files/1917964b-7ba3-4a14-ab52-e983843c2ad2

0 · Reply

bavramidis Jun. 11 at 4:32 PM

$HOOK Total POS. I continue to hope for the best but have been in this for years and nothing but down down down. Only reason I'm not selling my entire position is cause I'm down so bad....

2 · Reply

Bongostarjr Jun. 11 at 9:26 AM

$HOOK wow they said they may not be any cash left to distribute. Unbelievable. I am out

1 · Reply

superjeffy Jun. 10 at 2:16 PM

$HOOK out not waiting to see if anything leftover

0 · Reply

Wildsens Jun. 9 at 8:22 PM

$HOOK Almost the end. Maybe Some money left. Maybe not: https://ir.hookipapharma.com/static-files/7d443e59-1b21-4166-beea-0798d0cbd270

0 · Reply

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Jan 10, 2025, 2:00 AM EST - 6 months ago

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

Jan 8, 2025, 11:23 AM EST - 6 months ago

HOOKIPA Pharma Inc - FORM 8 (OPD)

Jan 7, 2025, 4:05 PM EST - 6 months ago

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

Jan 6, 2025, 2:00 AM EST - 6 months ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Jan 2, 2025, 2:00 AM EST - 6 months ago

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Nov 11, 2024, 4:05 PM EST - 8 months ago

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Oct 31, 2024, 9:17 AM EDT - 8 months ago

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

Oct 30, 2024, 7:30 AM EDT - 8 months ago

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Sep 24, 2024, 7:30 AM EDT - 10 months ago

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Sep 17, 2024, 8:00 AM EDT - 10 months ago

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

Aug 30, 2024, 8:00 AM EDT - 11 months ago

HOOKIPA Pharma Announces Board of Directors Changes

Aug 28, 2024, 8:57 AM EDT - 11 months ago

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 11 months ago

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 22, 2024, 8:30 AM EDT - 1 year ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Jul 8, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

Jul 1, 2024, 4:31 PM EDT - 1 year ago

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Jun 4, 2024, 1:00 PM EDT - 1 year ago

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

May 30, 2024, 4:30 PM EDT - 1 year ago

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

May 23, 2024, 5:01 PM EDT - 1 year ago

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

May 9, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 25, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

Apr 24, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

Apr 22, 2024, 2:20 PM EDT - 1 year ago

Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts

Apr 16, 2024, 4:30 PM EDT - 1 year ago

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Apr 10, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

Mar 22, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Mar 6, 2024, 7:01 AM EST - 1 year ago

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Jan 29, 2024, 8:01 AM EST - 1 year ago

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Jan 16, 2024, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Dec 21, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Nov 20, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Nov 9, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 12:01 PM EDT - 1 year ago

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

Nov 2, 2023, 4:01 PM EDT - 1 year ago

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

Oct 22, 2023, 6:01 AM EDT - 1 year ago

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Oct 18, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Sep 13, 2023, 8:45 AM EDT - 1 year ago

HOOKIPA Announces Executive Leadership Change

Sep 12, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Sep 6, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma to participate in upcoming investor conferences in September

Aug 10, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 3, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

Jun 10, 2023, 5:00 AM EDT - 2 years ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 31, 2023, 9:30 PM EDT - 2 years ago

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

May 31, 2023, 4:45 PM EDT - 2 years ago

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

May 11, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

May 4, 2023, 7:02 AM EDT - 2 years ago

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

May 4, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

Apr 26, 2023, 11:30 AM EDT - 2 years ago

HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO

superjeffy Jul. 2 at 5:56 PM

$HOOK or cash out now and get your whole $1.28 a share now

1 · Reply

Wildsens Jun. 30 at 9:31 PM

$HOOK New PR. It takes 3 years and you get 1.28 - 1.72 (probably). https://ir.hookipapharma.com/static-files/11f0658d-d3b3-44ca-aaf1-b7a89d34500d#page48

1 · Reply

DollaNugs Jun. 30 at 2:13 PM

$HOOK

0 · Reply

dcljr521 Jun. 30 at 1:41 PM

$HOOK is there any hope left?

0 · Reply

wyoming2020 Jun. 28 at 7:44 PM

3 · Reply

Wildsens Jun. 16 at 8:21 PM

$HOOK More info: https://ir.hookipapharma.com/static-files/1917964b-7ba3-4a14-ab52-e983843c2ad2

0 · Reply

bavramidis Jun. 11 at 4:32 PM

$HOOK Total POS. I continue to hope for the best but have been in this for years and nothing but down down down. Only reason I'm not selling my entire position is cause I'm down so bad....

2 · Reply

Bongostarjr Jun. 11 at 9:26 AM

$HOOK wow they said they may not be any cash left to distribute. Unbelievable. I am out

1 · Reply

superjeffy Jun. 10 at 2:16 PM

$HOOK out not waiting to see if anything leftover

0 · Reply

Wildsens Jun. 9 at 8:22 PM

$HOOK Almost the end. Maybe Some money left. Maybe not: https://ir.hookipapharma.com/static-files/7d443e59-1b21-4166-beea-0798d0cbd270

0 · Reply

superjeffy Jun. 3 at 3:00 PM

$HOOK The deal’s completion is subject to several closing conditions, including the approval of HOOKIPA’s (NASDAQ:HOOK) stockholders. https://seekingalpha.com/news/4451640-hookipa-stock-gains-gilead-eyes-assets

0 · Reply

slapslikeanass Jun. 3 at 8:52 AM

$HOOK 👀

0 · Reply

superjeffy Jun. 3 at 12:15 AM

$HOOK how come announcement isn’t on Hookipa or Gileads website?

1 · Reply

Hanaleimike May. 29 at 2:08 PM

$HOOK so do we have to sell? Or does that happen automatically when the buyout occurs?

2 · Reply

dcljr521 May. 27 at 2:53 PM

$HOOK so is Gilead gonna purchase HOOK or they are purchasing just the assets then HOOK is dissolving afterwards? I read that the market capitalization is 19m but Gilead is buying out for 10 m? I’m confused

3 · Reply

mtrader007 May. 25 at 11:03 PM

$HOOK serial diluter. Bs biotech news and raise money with offerings. do not fall in love with penny stocks. Listen to this million dollar trader! https://youtube.com/shorts/PBpxhmIKwfE?si=ukOXPeJHAJopTDAp

0 · Reply

wallstjam May. 25 at 5:03 AM

$HOOK nuts! I will return

0 · Reply

Lucky411 May. 25 at 3:43 AM

$HOOK

0 · Reply

Lucky411 May. 25 at 3:42 AM

$HOOK

0 · Reply

Lucky411 May. 25 at 3:42 AM

$HOOK $SCLX

0 · Reply

Lucky411 May. 25 at 3:42 AM

$HOOK

0 · Reply

GDog877 May. 25 at 1:12 AM

$HOOK Did you know the capital loss deduction limit has been stuck at $3,000 since 1978? That’s nearly 50 years with zero adjustment for inflation. Imagine still being limited to a $3K deduction 30 years from now—while everything else keeps getting more expensive. That’s why I support the Capital Loss Inflation Fairness Act (H.R. 2684), which would raise the limit and adjust it for inflation going forward... Most retail investors will take losses at some point. This bill is a common-sense update that reflects today’s economic reality. 👉 You can learn more about the bill here: https://norman.house.gov/news/documentsingle.aspx?DocumentID=1611 📞 Find your representative and ask them to support it: www.house.gov/representatives/find-your-representative

0 · Reply

Market Cap	14.99M
Revenue (ttm)	43.95M
Net Income (ttm)	-43.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-98.98%
Debt to Equity Ratio	0.00

Volume	52,000
Avg Vol	141,708
Day's Range	N/A - N/A
Shares Out	12.19M
Stochastic %K	4%
Beta	0.89
Analysts	Sell
Price Target	$4.50